Form D · Pharmaceuticals
Revance Therapeutics, Inc.
Newark, CA · CIK 0001479290
Offering snapshot reported Oct 23, 2013 · SEC filing
- Reported sold
- $10M Offering amount: $30M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 8, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 23, 2013 | Initial | $10,000,000 | No comparison | 4 | SEC filing |
| Feb 22, 2013 | Initial | $5,000,001 | No comparison | 4 | SEC filing |
| Jan 9, 2013 | Amendment | $63,360,183 | $12,440,992vs Sep 14, 2012 | 33 | SEC filing |
| Sep 14, 2012 | Amendment | $50,919,191 | $45,919,191vs Feb 3, 2011 | 33 | SEC filing |
| Oct 6, 2011 | Initial | $0 | No comparison | 1 | SEC filing |
| Jun 14, 2011 | Amendment | $45,000,000 | $40,000,000vs Feb 3, 2011 | 23 | SEC filing |
| Feb 3, 2011 | Initial | $5,000,000 | No comparison | 23 | SEC filing |
| Nov 18, 2010 | Amendment | $36,236,932 | $1,799,967vs Aug 23, 2010 | 27 | SEC filing |
| Aug 23, 2010 | Amendment | $34,436,965 | $999,995vs Jun 1, 2010 | 18 | SEC filing |
| Jun 1, 2010 | Amendment | $33,436,970 | $7,814,880vs Dec 23, 2009 | 16 | SEC filing |
| Dec 23, 2009 | Initial | $25,622,090 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-205127
Source: Form D, filed Oct 23, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| L. Daniel Browne | Director, Executive |
| Daniel L. Browne | Director, Executive |
| Robert Byrnes | Director |
| Ron Eastman | Director |
| Ronald Eastman | Director |
| Phyllis Gardner | Director |
| Jim Glasheen | Director |
| Frank Kung | Director |
| Vicente Trelles | Director |
| Jonathan Tunnicliffe | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
7555 Gateway Blvd.
Newark, CA, 94560
Newark, CA, 94560